Data from the prospective study by the Spanish Network on Mastocytosis (REMA) demonstrated that 81% of patients with advanced SM expressed D816V KIT in ≥2 bone marrow myeloid cell populations, compared with 27% of patients with good-prognosis SM, including ISM (15). This evidence concerns the gene KIT and systemic mastocytosis.